Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study

BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://ncbi.nlm.nih.gov/pubmed/32770690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0216
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados